These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 7520416)

  • 1. Immunogenic and antigenic properties of a heptavalent high-molecular-weight O-polysaccharide vaccine derived from Pseudomonas aeruginosa.
    Hatano K; Boisot S; DesJardins D; Wright DC; Brisker J; Pier GB
    Infect Immun; 1994 Sep; 62(9):3608-16. PubMed ID: 7520416
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Complex serology and immune response of mice to variant high-molecular-weight O polysaccharides isolated from Pseudomonas aeruginosa serogroup O2 strains.
    Hatano K; Pier GB
    Infect Immun; 1998 Aug; 66(8):3719-26. PubMed ID: 9673254
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Biologic activities of antibodies to the neutral-polysaccharide component of the Pseudomonas aeruginosa lipopolysaccharide are blocked by O side chains and mucoid exopolysaccharide (alginate).
    Hatano K; Goldberg JB; Pier GB
    Infect Immun; 1995 Jan; 63(1):21-6. PubMed ID: 7528730
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Construction and characterization of a Pseudomonas aeruginosa mucoid exopolysaccharide-alginate conjugate vaccine.
    Theilacker C; Coleman FT; Mueschenborn S; Llosa N; Grout M; Pier GB
    Infect Immun; 2003 Jul; 71(7):3875-84. PubMed ID: 12819072
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Specificity and function of murine monoclonal antibodies and immunization-induced human polyclonal antibodies to lipopolysaccharide subtypes of Pseudomonas aeruginosa serogroup 06.
    Pier GB; Koles NL; Meluleni G; Hatano K; Pollack M
    Infect Immun; 1994 Apr; 62(4):1137-43. PubMed ID: 8132318
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pseudomonas aeruginosa antigens as potential vaccines.
    Stanislavsky ES; Lam JS
    FEMS Microbiol Rev; 1997 Nov; 21(3):243-77. PubMed ID: 9451816
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Construction and characterization of a live, attenuated aroA deletion mutant of Pseudomonas aeruginosa as a candidate intranasal vaccine.
    Priebe GP; Brinig MM; Hatano K; Grout M; Coleman FT; Pier GB; Goldberg JB
    Infect Immun; 2002 Mar; 70(3):1507-17. PubMed ID: 11854239
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and immunogenicity of high molecular weight polysaccharide vaccine from immunotype 1 Pseudomonas aeruginosa.
    Pier GB
    J Clin Invest; 1982 Feb; 69(2):303-8. PubMed ID: 6799548
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A live-attenuated Pseudomonas aeruginosa vaccine elicits outer membrane protein-specific active and passive protection against corneal infection.
    Zaidi TS; Priebe GP; Pier GB
    Infect Immun; 2006 Feb; 74(2):975-83. PubMed ID: 16428743
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mucosal vaccination with a multivalent, live-attenuated vaccine induces multifactorial immunity against Pseudomonas aeruginosa acute lung infection.
    Kamei A; Coutinho-Sledge YS; Goldberg JB; Priebe GP; Pier GB
    Infect Immun; 2011 Mar; 79(3):1289-99. PubMed ID: 21149583
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Polysaccharide antigens of Pseudomonas aeruginosa.
    Pier GB
    Rev Infect Dis; 1988; 10 Suppl 2():S337-40. PubMed ID: 3142017
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunologic basis for mouse protection provided by high-molecular-weight polysaccharide from immunotype 1 Pseudomonas aeruginosa.
    Markham RB; Pier GB
    Rev Infect Dis; 1983; 5 Suppl 5():S957-62. PubMed ID: 6419317
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Isolation, structure, and immunogenicity of Pseudomonas aeruginosa immunotype 4 high-molecular-weight polysaccharide.
    Pier GB; Pollack M
    Infect Immun; 1989 Feb; 57(2):426-31. PubMed ID: 2492260
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunochemistry of Pseudomonas aeruginosa lipopolysaccharides and high-molecular-weight polysaccharides.
    Pier GB
    Rev Infect Dis; 1983; 5 Suppl 5():S950-6. PubMed ID: 6197738
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Human immune response to Pseudomonas aeruginosa mucoid exopolysaccharide (alginate) vaccine.
    Pier GB; DesJardin D; Grout M; Garner C; Bennett SE; Pekoe G; Fuller SA; Thornton MO; Harkonen WS; Miller HC
    Infect Immun; 1994 Sep; 62(9):3972-9. PubMed ID: 8063415
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Structural analysis and immunogenicity of Pseudomonas aeruginosa immunotype 2 high molecular weight polysaccharide.
    Pier GB; Bennett SE
    J Clin Invest; 1986 Feb; 77(2):491-5. PubMed ID: 3080477
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and immunogenicity of a polyvalent Pseudomonas aeruginosa O-polysaccharide-toxin A vaccine in humans.
    Cryz SJ; Sadoff JC; Cross AS; Fürer E
    Antibiot Chemother (1971); 1989; 42():177-83. PubMed ID: 2512836
    [No Abstract]   [Full Text] [Related]  

  • 18. Protection against fatal Pseudomonas aeruginosa pneumonia in mice after nasal immunization with a live, attenuated aroA deletion mutant.
    Priebe GP; Meluleni GJ; Coleman FT; Goldberg JB; Pier GB
    Infect Immun; 2003 Mar; 71(3):1453-61. PubMed ID: 12595463
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Octavalent Pseudomonas aeruginosa O-polysaccharide-toxin A conjugate vaccine.
    Cryz SJ; Sadoff JC; Fürer E
    Microb Pathog; 1989 Jan; 6(1):75-80. PubMed ID: 2733597
    [TBL] [Abstract][Full Text] [Related]  

  • 20. IL-17 is a critical component of vaccine-induced protection against lung infection by lipopolysaccharide-heterologous strains of Pseudomonas aeruginosa.
    Priebe GP; Walsh RL; Cederroth TA; Kamei A; Coutinho-Sledge YS; Goldberg JB; Pier GB
    J Immunol; 2008 Oct; 181(7):4965-75. PubMed ID: 18802100
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.